NBT Bank N A NY decreased its position in Bristol-Myers Squibb Company (NYSE:BMY) by 1.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 119,922 shares of the biopharmaceutical company’s stock after selling 1,200 shares during the period. Bristol-Myers Squibb makes up approximately 1.1% of NBT Bank N A NY’s holdings, making the stock its 25th biggest position. NBT Bank N A NY’s holdings in Bristol-Myers Squibb were worth $6,682,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in BMY. Tradewinds Capital Management LLC boosted its stake in Bristol-Myers Squibb by 34.6% in the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 500 shares in the last quarter. Blue Chip Partners Inc. boosted its stake in Bristol-Myers Squibb by 0.8% in the 1st quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after purchasing an additional 17 shares in the last quarter. Proficio Capital Partners LLC boosted its stake in Bristol-Myers Squibb by 29.6% in the 1st quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 504 shares in the last quarter. American National Bank boosted its stake in Bristol-Myers Squibb by 11.7% in the 2nd quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 225 shares in the last quarter. Finally, Heritage Trust Co bought a new position in Bristol-Myers Squibb in the 1st quarter worth about $123,000. Institutional investors own 69.51% of the company’s stock.

A number of brokerages have weighed in on BMY. Vetr lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $64.20 target price for the company. in a research report on Tuesday, August 22nd. Citigroup Inc. set a $72.00 target price on Bristol-Myers Squibb and gave the stock a “buy” rating in a research report on Wednesday, October 25th. BMO Capital Markets set a $49.00 target price on Bristol-Myers Squibb and gave the stock a “sell” rating in a research report on Thursday, October 26th. Credit Suisse Group set a $58.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Wednesday, August 16th. Finally, Cowen and Company set a $65.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Monday, August 14th. One analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus target price of $64.93.

In related news, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the transaction, the senior vice president now directly owns 46,297 shares in the company, valued at approximately $2,777,820. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.23% of the company’s stock.

TRADEMARK VIOLATION WARNING: “NBT Bank N A NY Has $6.68 Million Position in Bristol-Myers Squibb Company (BMY)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.thecerbatgem.com/2017/11/17/nbt-bank-n-a-ny-has-6-68-million-position-in-bristol-myers-squibb-company-bmy.html.

Bristol-Myers Squibb Company (NYSE:BMY) opened at $61.87 on Friday. The stock has a market capitalization of $99,953.27, a P/E ratio of 20.63, a P/E/G ratio of 2.41 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. Bristol-Myers Squibb Company has a 52 week low of $46.01 and a 52 week high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). The company had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The company’s revenue was up 6.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.77 earnings per share. research analysts predict that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 1st. Investors of record on Friday, October 6th were paid a dividend of $0.39 per share. The ex-dividend date was Thursday, October 5th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.52%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 61.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.